Download PDF
Thromb Haemost 2011; 106(02): 185-186
DOI: 10.1160/TH11-05-0335
Invited Editorial Focus
Schattauer GmbH

Atorvastatin and its collateral effects on microparticles

Silvia Montoro-García
1   Haemostasis Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
2   Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
,
Gregory Y. H. Lip
1   Haemostasis Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
,
Eduard Shantsila
1   Haemostasis Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
› Author Affiliations
Further Information

Publication History

Received: 10 May 2011

Accepted after major revision: 17 May 2011

Publication Date:
25 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Shantsila E, Kamphuisen PW, Lip GY. Circulating microparticles in cardiovascular disease: implications for atherogenesis and atherothrombosis. J Thromb Haemost 2010; 8: 2358-2368.
    CrossrefPubMedGoogle Scholar
  • 2 Auwerda JJ, Yuana Y, Osanto S. et al. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost 2011; 105: 14-20.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Huisse MG, Ajzenberg N, Feldman L. et al. Microparticle-linked tissue factor activity and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation myocardial infarction. Thromb Haemost 2009; 101: 734-740.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 van Tits LJ, van Heerde WL, Landburg PP. et al. Plasma annexin A5 and microparticle phosphatidylserine levels are elevated in sickle cell disease and increase further during painful crisis. Biochem Biophys Res Commun 2009; 390: 161-164.
    CrossrefPubMedGoogle Scholar
  • 5 Tramontano AF, Lyubarova R, Tsiakos J. et al. Circulating endothelial microparticles in diabetes mellitus. Mediators Inflamm 2010; 2010: 250476.
    CrossrefPubMedGoogle Scholar
  • 6 Tantawy AA, Matter RM, Hamed AA. et al. Platelet microparticles in immune thrombocytopenic purpura in pediatrics. Pediatr Hematol Oncol 2010; 27: 283-296.
    CrossrefPubMedGoogle Scholar
  • 7 Leroyer AS, Anfosso F, Lacroix R. et al. Endothelial-derived microparticles: Biological conveyors at the crossroad of inflammation, thrombosis and angiogenesis. Thromb Haemost 2010; 104: 456-463.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Chen YW, Chen JK, Wang JS. Strenuous exercise promotes shear-induced thrombin generation by increasing the shedding of procoagulant microparticles from platelets. Thromb Haemost 2010; 104: 293-301.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Mullier F, Bailly N, Cornet Y. et al. Contribution of platelet microparticles generation assay to the diagnosis of type II heparin-induced thrombocytopenia. Thromb Haemost 2010; 103: 1277-1281.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Morel O, Toti F, Hugel B. et al. Cellular microparticles: a disseminated storage pool of bioactive vascular effectors. Curr Opin Hematol 2004; 11: 156-164.
    CrossrefPubMedGoogle Scholar
  • 11 Tramontano AF, O’Leary J, Black AD. et al. Statin decreases endothelial microparticle release from human coronary artery endothelial cells: implication for the Rho-kinase pathway. Biochem Biophys Res Commun 2004; 320: 4-38.
    PubMedGoogle Scholar
  • 12 Diamant M, Tushuizen ME, Abid-Hussein MN. et al. Simvastatin-induced endothelial cell detachment and microparticle release are prenylation dependent. Thromb Haemost 2008; 100: 489-497.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Tehrani S, Mobarrez F, Antovic A. et al. Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia. Thromb Res 2010; 126: e225-231.
    CrossrefPubMedGoogle Scholar
  • 14 Makin AJ, Chung NA, Silverman SH. et al. Indices of thrombogenesis, endothelial damage and platelet function following percutaneous peripheral artery angiography and angioplasty for peripheral vascular disease. Pathophysiol Haemost Thromb 2003; 33: 102-108.
    CrossrefPubMedGoogle Scholar
  • 15 von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and vascular disease. Circ Res 2007; 100: 27-40.
    CrossrefPubMedGoogle Scholar
  • 16 Alkhatatbeh MJ, Mhaidat NM, Enjeti AK. et al. The putative diabetic plasma marker, soluble CD36, is non-cleaved, non-soluble and entirely associated with microparticles. J Thromb Haemost 2011; 9: 844-851.
    CrossrefPubMedGoogle Scholar
  • 17 Mobarrez F, He S, Bröijersen A. et al. Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease. Thromb Haemost 2011; 106: 344-352.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Undas A, Kaczmarek P, Sladek K. et al. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment. Thromb Haemost 2009; 102: 1176-1182.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Varughese GI, Patel JV, Lip GY. et al. Novel concepts of statin therapy for cardiovascular risk reduction in hypertension. Curr Pharm Des 2006; 12: 1593-1609.
    CrossrefPubMedGoogle Scholar
  • 20 Fu Y, Zhou J, Li H. et al. Daunorubicin induces procoagulant activity of cultured endothelial cells through phosphatidylserine exposure and microparticles release. Thromb Haemost. 2010; 104: 1235-1241.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Connor DE, Exner T, Ma DD. et al. The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib. Thromb Haemost 2010; 103: 1044-1052.
    Article in Thieme ConnectPubMedGoogle Scholar